Which has better valuation and earnings, CTKB or ALNT?

Allient has higher revenue and earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Allient, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cytek Biosciences $201.49M 2.84 -$66.54M -$0.57 N/A Allient $554.48M 3.16 $22.03M $1.43 71.98

Does the media refer more to CTKB or ALNT?

In the previous week, Allient had 1 more articles in the media than Cytek Biosciences. MarketBeat recorded 3 mentions for Allient and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 1.23 beat Allient's score of 0.53 indicating that Cytek Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytek Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allient 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, ALMR or CTKB?

Alamar Biosciences has higher earnings, but lower revenue than Cytek Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alamar Biosciences $87.16M 21.54 N/A N/A N/A Cytek Biosciences $201.49M 2.84 -$66.54M -$0.57 N/A

Does the media prefer ALMR or CTKB?

In the previous week, Alamar Biosciences had 1 more articles in the media than Cytek Biosciences. MarketBeat recorded 3 mentions for Alamar Biosciences and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 1.23 beat Alamar Biosciences' score of 0.63 indicating that Cytek Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alamar Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytek Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CTKB or TRNS?

In the previous week, Transcat had 3 more articles in the media than Cytek Biosciences. MarketBeat recorded 5 mentions for Transcat and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 1.23 beat Transcat's score of 0.75 indicating that Cytek Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytek Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Transcat 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cytek Biosciences (CTKB) Competitors

$4.43 +0.09 (+2.07%)

Closing price 04:00 PM Eastern

Extended Trading

$4.43 +0.00 (+0.11%)

As of 04:51 PM Eastern

Compare

CTKB vs. ALNT, ALMR, EYPT, TRNS, and FEIM

Should you buy Cytek Biosciences stock or one of its competitors? MarketBeat compares Cytek Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cytek Biosciences include Allient (ALNT), Alamar Biosciences (ALMR), Eyepoint Pharmaceuticals (EYPT), Transcat (TRNS), and Frequency Electronics (FEIM). These companies are all part of the "measuring and control equipment" industry.

How does Cytek Biosciences compare to Allient?

Cytek Biosciences (NASDAQ:CTKB) and Allient (NASDAQ:ALNT) are both small-cap measuring and control equipment companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

In the previous week, Allient had 1 more articles in the media than Cytek Biosciences. MarketBeat recorded 3 mentions for Allient and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 1.23 beat Allient's score of 0.53 indicating that Cytek Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Allient	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Allient has higher revenue and earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Allient, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	2.84	-$66.54M	-$0.57	N/A
Allient	$554.48M	3.16	$22.03M	$1.43	71.98

Cytek Biosciences currently has a consensus target price of $5.69, suggesting a potential upside of 28.39%. Allient has a consensus target price of $77.33, suggesting a potential downside of 24.87%. Given Cytek Biosciences' higher probable upside, equities research analysts plainly believe Cytek Biosciences is more favorable than Allient.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Allient	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Cytek Biosciences has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Allient has a beta of 1.63, meaning that its share price is 63% more volatile than the broader market.

Allient has a net margin of 4.25% compared to Cytek Biosciences' net margin of -36.25%. Allient's return on equity of 12.47% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-36.25%	-10.07%	-7.56%
Allient	4.25%	12.47%	6.37%

69.5% of Cytek Biosciences shares are held by institutional investors. Comparatively, 61.6% of Allient shares are held by institutional investors. 10.4% of Cytek Biosciences shares are held by insiders. Comparatively, 15.0% of Allient shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Allient beats Cytek Biosciences on 13 of the 16 factors compared between the two stocks.

How does Cytek Biosciences compare to Alamar Biosciences?

Alamar Biosciences (NASDAQ:ALMR) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap measuring and control equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Alamar Biosciences has higher earnings, but lower revenue than Cytek Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alamar Biosciences	$87.16M	21.54	N/A	N/A	N/A
Cytek Biosciences	$201.49M	2.84	-$66.54M	-$0.57	N/A

In the previous week, Alamar Biosciences had 1 more articles in the media than Cytek Biosciences. MarketBeat recorded 3 mentions for Alamar Biosciences and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 1.23 beat Alamar Biosciences' score of 0.63 indicating that Cytek Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alamar Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytek Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

69.5% of Cytek Biosciences shares are owned by institutional investors. 10.4% of Cytek Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Alamar Biosciences has a net margin of 0.00% compared to Cytek Biosciences' net margin of -36.25%. Alamar Biosciences' return on equity of 0.00% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alamar Biosciences	N/A	N/A	N/A
Cytek Biosciences	-36.25%	-10.07%	-7.56%

Alamar Biosciences currently has a consensus target price of $30.00, indicating a potential upside of 10.74%. Cytek Biosciences has a consensus target price of $5.69, indicating a potential upside of 28.39%. Given Cytek Biosciences' higher probable upside, analysts plainly believe Cytek Biosciences is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alamar Biosciences	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Alamar Biosciences beats Cytek Biosciences on 7 of the 12 factors compared between the two stocks.

How does Cytek Biosciences compare to Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Eyepoint Pharmaceuticals has a beta of 1.72, meaning that its stock price is 72% more volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market.

Cytek Biosciences has a net margin of -36.25% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Cytek Biosciences' return on equity of -10.07% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%
Cytek Biosciences	-36.25%	-10.07%	-7.56%

Cytek Biosciences has higher revenue and earnings than Eyepoint Pharmaceuticals. Cytek Biosciences is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	38.15	-$231.96M	-$3.50	N/A
Cytek Biosciences	$201.49M	2.84	-$66.54M	-$0.57	N/A

In the previous week, Eyepoint Pharmaceuticals and Eyepoint Pharmaceuticals both had 2 articles in the media. Cytek Biosciences' average media sentiment score of 1.23 beat Eyepoint Pharmaceuticals' score of 0.94 indicating that Cytek Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Eyepoint Pharmaceuticals	Positive
Cytek Biosciences	Positive

Eyepoint Pharmaceuticals currently has a consensus price target of $37.83, suggesting a potential upside of 165.03%. Cytek Biosciences has a consensus price target of $5.69, suggesting a potential upside of 28.39%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Comparatively, 10.4% of Cytek Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Eyepoint Pharmaceuticals and Cytek Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Cytek Biosciences compare to Transcat?

Cytek Biosciences (NASDAQ:CTKB) and Transcat (NASDAQ:TRNS) are both small-cap measuring and control equipment companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Cytek Biosciences has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Transcat has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market.

In the previous week, Transcat had 3 more articles in the media than Cytek Biosciences. MarketBeat recorded 5 mentions for Transcat and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 1.23 beat Transcat's score of 0.75 indicating that Cytek Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Transcat	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytek Biosciences presently has a consensus price target of $5.69, suggesting a potential upside of 28.39%. Transcat has a consensus price target of $105.33, suggesting a potential upside of 13.54%. Given Cytek Biosciences' higher possible upside, equities research analysts clearly believe Cytek Biosciences is more favorable than Transcat.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Transcat	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Transcat has higher revenue and earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	2.84	-$66.54M	-$0.57	N/A
Transcat	$331.88M	2.61	$5.38M	$0.58	159.95

69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 98.3% of Transcat shares are owned by institutional investors. 10.4% of Cytek Biosciences shares are owned by company insiders. Comparatively, 2.8% of Transcat shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Transcat has a net margin of 1.62% compared to Cytek Biosciences' net margin of -36.25%. Transcat's return on equity of 5.84% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-36.25%	-10.07%	-7.56%
Transcat	1.62%	5.84%	3.78%

Summary

Transcat beats Cytek Biosciences on 11 of the 17 factors compared between the two stocks.

How does Cytek Biosciences compare to Frequency Electronics?

Cytek Biosciences (NASDAQ:CTKB) and Frequency Electronics (NASDAQ:FEIM) are both small-cap measuring and control equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Frequency Electronics has a net margin of 10.78% compared to Cytek Biosciences' net margin of -36.25%. Frequency Electronics' return on equity of 12.69% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-36.25%	-10.07%	-7.56%
Frequency Electronics	10.78%	12.69%	7.84%

Cytek Biosciences presently has a consensus price target of $5.69, suggesting a potential upside of 28.39%. Frequency Electronics has a consensus price target of $43.67, suggesting a potential downside of 34.19%. Given Cytek Biosciences' higher probable upside, analysts clearly believe Cytek Biosciences is more favorable than Frequency Electronics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Frequency Electronics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00

69.5% of Cytek Biosciences shares are held by institutional investors. Comparatively, 58.6% of Frequency Electronics shares are held by institutional investors. 10.4% of Cytek Biosciences shares are held by insiders. Comparatively, 28.0% of Frequency Electronics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cytek Biosciences has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, Frequency Electronics has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

In the previous week, Cytek Biosciences had 1 more articles in the media than Frequency Electronics. MarketBeat recorded 2 mentions for Cytek Biosciences and 1 mentions for Frequency Electronics. Frequency Electronics' average media sentiment score of 1.89 beat Cytek Biosciences' score of 1.23 indicating that Frequency Electronics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cytek Biosciences	Positive
Frequency Electronics	Very Positive

Frequency Electronics has lower revenue, but higher earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Frequency Electronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	2.84	-$66.54M	-$0.57	N/A
Frequency Electronics	$69.81M	9.35	$23.69M	$0.75	88.47

Summary

Frequency Electronics beats Cytek Biosciences on 11 of the 17 factors compared between the two stocks.

Get Cytek Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTKB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTKB vs. The Competition

Export

Metric	Cytek Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$560.48M	$3.66B	$6.87B	$12.45B
Dividend Yield	N/A	2.20%	2.67%	6.16%
P/E Ratio	-7.77	20.90	27.51	24.87
Price / Sales	2.84	341.80	540.69	102.84
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	1.66	8.75	11.01	6.54
Net Income	-$66.54M	$23.81M	$3.57B	$336.70M
7 Day Performance	8.85%	3.64%	2.56%	3.31%
1 Month Performance	5.73%	1.64%	0.89%	1.68%
1 Year Performance	30.29%	69.47%	36.84%	31.96%

Cytek Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTKB Cytek Biosciences	2.7945 of 5 stars	$4.43 +2.1%	$5.69 +28.4%	+22.3%	$560.48M	$201.49M	N/A	500
ALNT Allient	3.6635 of 5 stars	$96.03 -2.8%	$77.33 -19.5%	+177.8%	$1.68B	$554.48M	44.70	2,478	Gap Down
ALMR Alamar Biosciences	3.7507 of 5 stars	$22.94 +0.7%	$30.00 +30.8%	N/A	$1.58B	$87.16M	N/A	222
EYPT Eyepoint Pharmaceuticals	2.9131 of 5 stars	$14.38 +4.7%	$31.80 +121.1%	+46.4%	$1.15B	$31.37M	N/A	120
TRNS Transcat	2.7892 of 5 stars	$89.46 -3.5%	$105.33 +17.7%	+7.6%	$866.35M	$331.88M	154.24	1,413	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTKB) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytek Biosciences (CTKB) Competitors

CTKB vs. ALNT, ALMR, EYPT, TRNS, and FEIM

How does Cytek Biosciences compare to Allient?

Summary

How does Cytek Biosciences compare to Alamar Biosciences?

Summary

How does Cytek Biosciences compare to Eyepoint Pharmaceuticals?

Summary

How does Cytek Biosciences compare to Transcat?

Summary

How does Cytek Biosciences compare to Frequency Electronics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTKB vs. The Competition

Cytek Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytek Biosciences (CTKB) Competitors

CTKB vs. ALNT, ALMR, EYPT, TRNS, and FEIM

How does Cytek Biosciences compare to Allient?

Does the media refer more to CTKB or ALNT?

Which has better valuation and earnings, CTKB or ALNT?

Do analysts prefer CTKB or ALNT?

Which has more volatility & risk, CTKB or ALNT?

Is CTKB or ALNT more profitable?

Do institutionals & insiders have more ownership in CTKB or ALNT?

Summary

How does Cytek Biosciences compare to Alamar Biosciences?

Which has preferable earnings & valuation, ALMR or CTKB?

Does the media prefer ALMR or CTKB?

Do insiders and institutionals believe in ALMR or CTKB?

Is ALMR or CTKB more profitable?

Do analysts recommend ALMR or CTKB?

Summary

How does Cytek Biosciences compare to Eyepoint Pharmaceuticals?

Which has more volatility and risk, EYPT or CTKB?

Is EYPT or CTKB more profitable?

Which has stronger valuation & earnings, EYPT or CTKB?

Does the media prefer EYPT or CTKB?

Do analysts rate EYPT or CTKB?

Do institutionals and insiders hold more shares of EYPT or CTKB?

Summary

How does Cytek Biosciences compare to Transcat?

Which has more volatility and risk, CTKB or TRNS?

Does the media favor CTKB or TRNS?

Do analysts recommend CTKB or TRNS?

Which has better valuation & earnings, CTKB or TRNS?

Do insiders and institutionals hold more shares of CTKB or TRNS?

Is CTKB or TRNS more profitable?

Summary

How does Cytek Biosciences compare to Frequency Electronics?

Is CTKB or FEIM more profitable?

Do analysts prefer CTKB or FEIM?

Do insiders and institutionals hold more shares of CTKB or FEIM?

Which has more risk and volatility, CTKB or FEIM?

Does the media prefer CTKB or FEIM?

Which has better earnings and valuation, CTKB or FEIM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTKB vs. The Competition

Cytek Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools